One of the 17 appraisals concerned an indication for first and later lines (crizotinib TA529) and another appraisal (atezolizumab TA584) included both first line treatment for PD-L1 expression of 0–49% and as well as later line when targeted therapy for EGFR-positive or ALK-positive NSCLC failed. This evidence concerns the gene EGFR and non-small cell lung carcinoma.